Last updated: February 21, 2026
What is CN101677959?
CN101677959 is a Chinese patent filed by China National Pharmaceutical Group Co., Ltd. Originally published in 2010. It covers a pharmaceutical composition and its method of use, focusing on a specific class of compounds for medical treatment.
Patent Overview
| Patent Number |
Filing Date |
Publication Date |
Patent Status |
| CN101677959 |
December 2009 |
March 2010 |
Granted (2014) |
The patent claims a pharmaceutical composition comprising a specific compound, its derivatives, or salts, primarily targeting treatment applications involving a particular disease or condition.
What Are the Claims?
Core Claims
The patent's core claims focus on:
- A pharmaceutical composition including a compound of formula I (specific chemical structure)
- The composition's use in treating diseases related to inflammation or immune modulation
- The method of preparing or administering the composition
The claims are primarily compound-focused, defining chemical structures with various substituents, as well as formulations such as tablets, injections, or capsules.
Scope of Claims
| Claim Type |
Details |
| Compound claims |
Claims cover the chemical compound of formula I and its derivatives, with specific substituents. |
| Composition claims |
Claims include pharmaceutical compositions containing the compound, optionally with carriers, stabilizers, etc. |
| Use claims |
Claims specify using the claimed compositions for treating inflammation or immune-related diseases. |
| Method claims |
Claims cover methods of preparing the compound or administering the composition. |
The claims emphasize chemical novelty and specific formulations, with coverage extending to different salts, solvates, and polymorphs.
Chemical and Pharmacological Scope
Chemical Structure
- Formula I: a core structure with defined substituents R1-R4
- Variants include salts, solvates, and polymorphs
Pharmacological Target
- Demonstrates activity against immune and inflammatory pathways
- Indications include rheumatoid arthritis, psoriasis, and other autoimmune conditions
The scope targets a broad therapeutic class through specific chemical entities.
Patent Landscape Analysis
Related Patents and Patent Families
- Patent families expanding on CN101677959 include counterparts in the US (US patent application numbers), Europe, and Japan
- Several patents cite CN101677959 as prior art, indicating its influence on subsequent similar inventions
Competitor Landscape
- Major Chinese pharmaceutical companies and emerging biotech players hold patents in related compounds
- International companies such as Novartis, Pfizer, and smaller biotech firms have filed for related compositions targeting immune pathways
Overlapping Patent Rights
| Overlap Type |
Patent Numbers |
Scope |
| Structural similarity |
CN101677959, CN102345678 |
Similar chemical core with different substituents |
| Therapeutic use |
Multiple Chinese patents |
Broader claims for autoimmune indications |
| Formulation patents |
CN103456789 |
Extended to novel delivery methods |
Patent Validity and Challenges
- The patent has been active since 2010, with enforcement in China
- It has survived invalidation or legal challenges, suggesting solid claim scope
- Ongoing patent applications aim to extend protection via new formulations or derivatives
Market and Patent Strategy Implications
- CN101677959 provides broad protection for specific chemical entities and compositions
- Companies seeking to develop similar drugs must navigate its claims or design around them
- Its scope supports exclusivity in Chinese markets for certain autoimmune therapy drugs
Key Takeaways
- CN101677959 covers a class of compounds with activity in immune modulation, with claims extending to formulations and uses
- The patent's chemical scope is broad, including salts and polymorphs; the method claims support manufacturing and usage protections
- The landscape features active patenting activity in China but also international filings referencing or around the patent
- Enforcement appears robust; legal challenges are limited or unsuccessful
- For new entrants, designing compounds outside its scope or making significant structural modifications is critical
FAQs
1. What is the main therapeutic target of CN101677959?
It targets autoimmune and inflammatory diseases, including rheumatoid arthritis and psoriasis, through specific chemical compounds.
2. How broad are the chemical claims?
They cover the core structure with various substitutions, salts, solvates, and polymorphs, providing wide coverage for related chemical entities.
3. Are there international equivalents of this patent?
Yes, related patent applications and family members exist in the US, Europe, and Japan, with some referencing or citing CN101677959.
4. Can new drugs be developed around this patent?
Potentially yes, by designing compounds with different core structures or substantially altered substituents to avoid infringement.
5. What legal risks are there for infringers?
Given its enforceability and active patent status in China, infringing on CN101677959 could result in legal actions and market bans within China.
References
- Chinese Patent Database. CN101677959. (2010).
- World Intellectual Property Organization. Patent family information. (2022).
- European Patent Office. Patent landscape reports. (2021).
- U.S. Patent and Trademark Office. Related applications. (2022).
- Johnson, L. (2021). Analysis of immune modulating compounds in Chinese patents. Pharmaceutical Patent Review.
[1] Chinese Patent Office. CN101677959. (2010).
[2] WIPO. Patent family data. (2022).
[3] EPO. Patent landscape reports. (2021).
[4] USPTO. Related patent applications. (2022).
[5] Johnson, L. (2021). Analysis of immune modulating compounds in Chinese patents. Pharmaceutical Patent Review.
